Virtual Library

Start Your Search

Florence Kurttila

Author of

  • +

    MA22 - Partnering with Patients to Understand Stigma, Disparities and Values Leading to Improved Lung Cancer Care (ID 154)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Advocacy
    • Presentations: 1
    • Now Available
    • +

      MA22.02 - The Impact of Patient Engagement on Study Design and Patient Recruitment in a Pragmatic Trial to Improve Cancer Care Delivery (Now Available) (ID 2388)

      15:45 - 17:15  |  Author(s): Florence Kurttila

      • Abstract
      • Presentation
      • Slides


      SWOG trial S1415CD is a pragmatic study comparing outcomes of Colony Stimulating Factor (CSF) use in usual care with care that uses guideline-informed standing CSF orders. A 21-person External Stakeholder Advisory Group (ESAG), including 10 patient partners, has informed the design, implementation, recruitment and dissemination planning for the study. Recruitment has been a challenge for study sites, specifically around approaching and consenting patients in the window between diagnosis and first cycle of chemotherapy. This abstract explores the impact of the ESAG patient partners on the patient recruitment process for S1415CD.


      Patient partners are convened each year over monthly teleconferences, one in-person meeting and targeted email communication. Patient partner input from 2014-present has been tracked and reviewed for impact on the patient recruitment process. After the start of accrual in October 2016, a teleconference was held in spring 2017 focused on barriers to patient accrual, specifically patient approach. Study sites submit monthly screening logs detailing reasons for patient ineligibility.


      Prior to the start of accrual, patient partners collaborated with the research team to create 2 resources to assist clinic staff with presenting the trial in lay terms: a patient brochure and a summary handout for clinical research associates (CRAs). CRAs reported high use of the brochure as a valuable, simple tool for explaining the trial to eligible patients. Patient partners were also engaged in developing consent forms for trial participants. In addition, patient partners developed strategies for approaching patients in the timeframe between diagnosis and first cycle of chemotherapy which were compiled into a document for study sites and incorporated into the trial’s frequently asked questions. Between October 2016-June 2017, the approach and consent process (i.e. the inability to consent patients in the narrow timeframe) accounted for 22% of all reported ineligible patients, however after the implementation of patient-formulated strategies, during June 2017-December 2018, the approach and consent process has accounted for only 10% of all reported ineligible patients.


      Sustained engagement and active participation of patient partners throughout S1415CD has provided unique experiential knowledge and feedback to improve the patient approach and consent process across study sites, leading to increased opportunities for patient recruitment. Engaging patient partners early and throughout the study design and conduct phases of the research has been successful in providing patient-centered solutions to recruitment and implementation challenges, including the challenge of timing, to ensure success in reaching the study accrual goals.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.